Evidence map›Paper›PMID 30877462›Full record

ArticleEuropean radiology2019

Prognostic value of baseline volumetric multiparametric MR imaging in neuroendocrine liver metastases treated with transarterial chemoembolization.

Yan Luo, Ankur Pandey, Mounes Aliyari Ghasabeh, Pallavi Pandey, Farnaz Najmi Varzaneh, Manijeh Zarghampour, Pegah Khoshpouri, Sanaz Ameli, Zhen Li, Daoyu Hu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yan LuoDepartment of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Ankur PandeyRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Nelson 143, Central Radiology, MRI, 600 North Wolfe Street, Room 143, Baltimore, MD, 21287, USA.
Mounes Aliyari GhasabehRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Nelson 143, Central Radiology, MRI, 600 North Wolfe Street, Room 143, Baltimore, MD, 21287, USA.
Pallavi PandeyRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Nelson 143, Central Radiology, MRI, 600 North Wolfe Street, Room 143, Baltimore, MD, 21287, USA.
Farnaz Najmi VarzanehRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Nelson 143, Central Radiology, MRI, 600 North Wolfe Street, Room 143, Baltimore, MD, 21287, USA.
Manijeh ZarghampourRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Nelson 143, Central Radiology, MRI, 600 North Wolfe Street, Room 143, Baltimore, MD, 21287, USA.
Pegah KhoshpouriRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Nelson 143, Central Radiology, MRI, 600 North Wolfe Street, Room 143, Baltimore, MD, 21287, USA.
Sanaz AmeliRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Nelson 143, Central Radiology, MRI, 600 North Wolfe Street, Room 143, Baltimore, MD, 21287, USA.
Zhen LiDepartment of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Daoyu HuDepartment of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
Ihab R KamelRussell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Nelson 143, Central Radiology, MRI, 600 North Wolfe Street, Room 143, Baltimore, MD, 21287, USA. ikamel@jhmi.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo determine whether baseline multiparametric MR imaging can predict overall survival (OS) and hepatic progression-free survival (HPFS) in patients with neuroendocrine liver metastases (NELMs) treated with transarterial chemoembolization (TACE).

methodsThis retrospective study included 84 NELMs patients treated with TACE. Tumor volume and volumetric measurements of arterial enhancement (AE), venous enhancement (VE), and apparent diffusion coefficient (ADC) were performed on baseline MR imaging. A maximum of one, two, and five index lesions were selected in each patient. OS was the primary endpoint and HPFS was the secondary endpoint. Prognostic values of volumetric multiparametric MR parameters for predicting OS and HPFS considering a maximum of one, two, and five index lesions were assessed.

resultsPrognostic values of volumetric multiparametric MR parameters for predicting OS and HPFS were similar regardless of the maximum number of index lesions. Multivariate survival analysis showed that baseline dominant tumor volume ≥ 73 cm

conclusionVolumetric enhancement values and tumor volume of the dominant lesion on baseline MR imaging may act as prognostic factors for OS and HPFS in NELMs patients treated with TACE. KEY POINTS: • High volumetric mean AE and VE, and low tumor volume of the dominant lesion on baseline MR imaging were associated with favorable OS and HPFS in NELMs patients treated with TACE. • Evaluation of multiple lesions does not provide additional information as compared to single lesion evaluation.

Indexed as

AdultAgedAntineoplastic AgentsChemoembolization, TherapeuticDiffusion Magnetic Resonance ImagingFemaleHumansInfusions, Intra-ArterialLiver NeoplasmsMaleMiddle AgedNeuroendocrine TumorsPrognosisRetrospective StudiesTumor BurdenAntineoplastic AgentsChemoembolizationLiver neoplasmsMagnetic resonance imagingNeuroendocrine tumorsPrognosis

Identifiers

PMID30877462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.